Medicine for treating human cerebral infarction

Abstract

The invention discloses a medicine for treating human cerebral infarction, and particularly relates to the field of medicines, the medicine is prepared from the following raw material medicines in percentage by mass: 11% of astragalus membranaceus, 7.7% of salvia miltiorrhiza, 9.9% of safflower, 3.3% of ligusticum wallichii, 7.7% of tabasheer, 5.5% of polygala tenuifolia, 4.4% of radix curcumae, 5.5% of rhizoma acori graminei, 2.2% of roasted rhizoma typhonii, 5.5% of radix cyathulae, 7.7% of earthworm, 4.4% of zaocys dhumnade, 3.3% of centipede, 4.4% of stiff silkworm, 6.6% of pangolin, 4.4% of scorpion, 2.1% of pearl powder and 4.4% of arisaema cum bile. The dosage form of the medicine is powder, capsules, tablets or pills. According to the medicine for treating human cerebral infarction disclosed by the invention, the problems that the existing traditional Chinese medicine compound is unclear in pharmacodynamic mechanism and insufficient in curative effect on intractable dysfunction when being used for treating cerebral infarction sequelae are solved through scientific matching of qi-tonifying, blood-activating, wind-expelling and collateral-dredging medicinal materials such as radix astragali, radix salviae miltiorrhizae, earthworm, scorpio and pangolin; the effects of remarkably improving the limb movement functions such as hemiplegia, leg dragging and pestling of the patient and promoting neural function recovery are achieved.

Description

Technical Field

[0001] This invention relates to the field of medicine, and in particular to a drug for treating cerebral infarction in humans. Background Technology

[0002] Current medical research indicates that post-stroke sequelae differ from transient neurological deficits. Even with conventional treatment and successful recanalization, complete recovery is not guaranteed; the sequelae may persist, progress, or recur, making functional restoration and prevention of disability extremely difficult. Although hospitals provide systematic rehabilitation treatments for stroke patients, such as exercise therapy, occupational therapy, and speech therapy, a significant proportion still suffer from varying degrees of functional impairment. Some patients may even face the pain of losing limb and speech functions in their future lives due to recurrence or complications. The existing technologies have the following limitations: While existing traditional Chinese medicine (TCM) compound formulas are used in the treatment of cerebral infarction, most have complex formulations, unclear mechanisms of action, and lack systematic preparation processes and quality control standards, leading to unstable clinical efficacy. Therefore, there is an urgent need for a scientifically formulated, standardized, effective, and low-side-effect TCM composition to meet the rehabilitation needs of patients with post-stroke sequelae. Summary of the Invention

[0003] The main objective of this invention is to provide a drug for treating cerebral infarction in humans, which can effectively solve the problems in the prior art such as unclear efficacy of drugs for treating sequelae of cerebral infarction, insufficient efficacy for treating intractable functional disorders, unstable efficacy due to non-standard preparation processes, and difficulty in recovering from swallowing and speech disorders.

[0004] To achieve the above objectives, the technical solution adopted by the present invention is as follows: A drug for treating cerebral infarction in humans comprises the following raw materials in weight percentages: Astragalus membranaceus 11%, Salvia miltiorrhiza 7.7%, Carthamus tinctorius 9.9%, Ligusticum chuanxiong 3.3%, Bambusa textilis 7.7%, Polygala tenuifolia 5.5%, Curcuma longa 4.4%, Acorus tatarinowii 5.5%, processed Aconitum carmichaelii 2.2%, Achyranthes bidentata 5.5%, Pheretima aspergillum 7.7%, Zaocys dhumnades 4.4%, Scolopendra subspinipes 3.3%, Bombyx mori 4.4%, Manis pentadactyla 6.6%, Buthus martensii 4.4%, Pearl powder 2.1%, Arisaema cum bile 4.4%.

[0005] Preferably, the dosage form of the drug is a powder, capsule, tablet or pill.

[0006] A method for preparing a drug for treating cerebral infarction in humans, comprising the following steps: S1: Astragalus membranaceus, Salvia miltiorrhiza, Carthamus tinctorius, Ligusticum chuanxiong, Bambusa textilis, Polygala tenuifolia, Curcuma longa, Acorus tatarinowii, processed Aconitum carmichaelii, and Achyranthes bidentata are pulverized and sieved to obtain the first group of medicinal powders; S2: Pheretima aspergillum, Zaocys dhumnades, and Scolopendra subspinipes are stir-fried with wine, pulverized, and sieved to obtain the second group of medicinal powders; S3: Bombyx mori is stir-fried, pulverized, and sieved to obtain the third group of medicinal powders; S4: Pangolin scales are scalded with sand, pulverized, and sieved to obtain the fourth group of medicinal powders; S5: Scorpion, pearl powder, and Arisaema cum Bile are pulverized and sieved to obtain the fifth group of medicinal powders; S6: The above five groups of medicinal powders are mixed evenly to obtain the drug.

[0007] Preferably, the mesh size of the sieve in S1, S2, S3, S4, and S5 is 80 to 200 mesh.

[0008] Preferably, the stir-frying in step S2 involves stir-frying the medicinal materials with rice wine until the surface of the medicinal materials is slightly dry.

[0009] Preferably, the sand-frying in step S4 involves stir-frying the pangolin with hot sand until the surface puffs up and turns golden yellow.

[0010] Preferably, the stir-frying in step S3 involves placing the silkworm pupae in a pot and stir-frying over low heat until the surface turns slightly yellow.

[0011] Preferably, the drug is used in the preparation of a medicine for improving sequelae of cerebral infarction, wherein the sequelae of cerebral infarction include at least one of hemiplegia, dysphagia, and dysarthria.

[0012] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention provides a drug for treating cerebral infarction in humans. Through the scientific combination of Astragalus membranaceus, Salvia miltiorrhiza, Pheretima aspergillum, Scorpio, Pangolin scales and other qi-invigorating and blood-activating and wind-dispelling and meridian-clearing herbs, it solves the problems of unclear efficacy mechanism and insufficient efficacy for intractable functional impairment in existing Chinese medicine compound prescriptions when treating sequelae of cerebral infarction. It achieves the effect of significantly improving the motor function of limbs such as hemiplegia, dragging the leg, and using crutches, and promoting the recovery of nerve function.

[0013] 2. This invention provides a drug for treating cerebral infarction in humans. By combining group processing methods such as stir-frying with wine, stir-frying with plain water, and scalding with sand with fine pulverization and sieving of 80-200 mesh, it solves the problems of non-standard traditional Chinese medicine preparation processes, which lead to unstable drug components and inconsistent clinical efficacy. It achieves the effect of optimizing drug activity, ensuring batch-to-batch quality uniformity, and thus ensuring stable and reliable efficacy.

[0014] 3. This invention provides a drug for treating cerebral infarction. Through the synergistic combination of herbs such as Acorus tatarinowii, Polygala tenuifolia, and Arisaema cum Bile, which open the orifices and resolve phlegm, and promote blood circulation and unblock the meridians, it solves the clinical problem of difficulty in recovery of symptoms such as dysphagia and dysarthria in the sequelae of cerebral infarction. It achieves the effect of improving the patient's swallowing function and speech clarity. No obvious adverse reactions were found in the whole treatment process, and the drug has a high safety effect. Attached Figure Description

[0015] Figure 1 This is a schematic diagram of the drug preparation process of the present invention. Detailed Implementation

[0016] To make the technical means, creative features, objectives, and effects of this invention easier to understand, the invention is further described below in conjunction with specific embodiments. Process parameters in the following embodiments that are not specifically specified are generally performed under conventional conditions or according to the manufacturer's recommendations.

[0017] Example 1: Drug Preparation Raw material preparation: Weigh the raw materials according to the following percentages based on a total weight of 455g: Astragalus membranaceus: 50.05g (11%), Salvia miltiorrhiza: 35.035g (7.7%), Carthamus tinctorius: 45.045g (9.9%), Ligusticum chuanxiong: 15.015g (3.3%), Bambusa textilis: 35.035g (7.7%), Polygala tenuifolia: 25.025g (5.5%), Curcuma longa: 20.02g (4.4%), Acorus tatarinowii: 25.025g (5.5%), and processed Aconitum carmichaelii: 10.01g (2.2%), Achyranthes bidentata: 25.025g (5.5%), Pheretima aspergillum: 35.035g (7.7%), Zaocys dhumnades: 20.02g (4.4%), Scolopendra subspinipes: 15.015g (3.3%), Bombyx mori: 20.02g (4.4%), Pangolin scales: 30.03g (6.6%), Scorpion: 20.02g (4.4%), Pearl powder: 9.555g (2.1%), Arisaema cum bile: 20.02g (4.4%); Preparation process: Preparation of the first group of medicinal powders: Take the above-weighed Astragalus membranaceus, Salvia miltiorrhiza, Carthamus tinctorius, Ligusticum chuanxiong, Bambusa textilis, Polygala tenuifolia, Curcuma longa, Acorus tatarinowii, processed Aconitum carmichaelii, and Achyranthes bidentata, mix them evenly; use a universal grinder to grind them, and pass them through a 100-mesh sieve to obtain the first group of medicinal powders for later use; Preparation of the second group of medicinal powder: Take the weighed earthworm, black-striped snake and centipede, mix them evenly, add an appropriate amount of rice wine, the mass ratio of medicinal materials to rice wine is 10:1, mix well, let it soak for 30 minutes, then put it in a frying pan and stir-fry over low heat until the surface of the medicinal materials darkens and becomes slightly dry, and emits its inherent aroma. Cool the medicinal materials after stir-frying with wine, pulverize them, and pass them through a 100-mesh sieve to obtain the second group of medicinal powder for later use. Preparation of the third group of medicinal powder: Take the weighed silkworms mentioned above, place them in a stir-frying pan, stir-fry over low heat until the surface turns slightly yellow and emits a fragrance, cool and then grind them into powder, pass them through a 100-mesh sieve to obtain the third group of medicinal powder, and set aside for later use. Preparation of the fourth group of medicinal powder: Take the weighed pangolin scales mentioned above, put the clean sand into a frying container, heat it over high heat until it becomes slippery, put in the pangolin scales, stir constantly, scald until the surface puffs up and turns golden yellow, sift out the sand, cool and crush it, pass it through a 100-mesh sieve to obtain the fourth group of medicinal powder, for later use. Preparation of the fifth group of medicinal powder: Take the weighed whole scorpion, pearl powder, and bile arisaema, mix them evenly, grind them directly, and pass them through a 100-mesh sieve to obtain the fifth group of medicinal powder, which is ready for use. Mixing and Packaging: Put all the first to fifth groups of powders prepared above into a mixer and mix for 30 minutes until uniform. Divide the mixed powder into 5g bags and seal them to obtain the drug powder for treating human cerebral infarction as described in this invention. In this embodiment, the universal pulverizer pulverizes for 2-5 minutes at a time, intermittently, to prevent the temperature from getting too high. During screening, all fine powder that can pass through a 100-mesh sieve is collected. The mixer is a three-dimensional motion mixer. After mixing, multiple random samples are taken, and the indicators such as tanshinone IIA are determined by HPLC. The relative standard deviation should be less than 5.0% to ensure uniform mixing.

[0018] Example 2: Preparation of drug capsules Take the mixed powder obtained in Example 1, fill it into empty capsules to make capsules, each capsule containing 0.5g of powder.

[0019] Example 3: Clinical Application and Effect Observation Twelve patients who met the diagnostic criteria for sequelae of cerebral infarction were selected. Their basic information is shown in the table below as a statistical table of cerebral infarction patients who have recovered. The patients took the drug powder prepared in Example 1 three times a day, 5g each time, with warm water below 40℃. It is contraindicated for pregnant women. Use with caution in patients allergic to insect drugs. Avoid raw, cold and greasy foods during the medication period. One course of treatment is three months, and two courses of treatment are taken consecutively. Statistical table of stroke survivors

[0020] Observation results: After taking the medication, all patients experienced varying degrees of improvement in limb motor function (such as hemiplegia, dragging legs, using crutches, and wheelchair use), swallowing function, and speech clarity. Statistical data showed that among the 12 patients, 100% achieved normal results or significant symptom improvement. Among them, patients with pre-stroke symptoms usually recovered their health after six months of medication; most patients with significant mobility impairments such as using crutches or wheelchairs were able to recover to walking independently or with crutches after nine months of medication. No adverse reactions related to this drug were found throughout the entire treatment and follow-up period.

[0021] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of the invention. Various changes and modifications can be made to the invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the present invention as claimed. The scope of protection of this invention is defined by the appended claims and their equivalents.

Claims

1. A drug for treating cerebral infarction in humans, characterized in that: The raw materials consist of the following percentages by weight: Astragalus membranaceus 11%, Salvia miltiorrhiza 7.7%, Carthamus tinctorius 9.9%, Ligusticum chuanxiong 3.3%, Bambusa textilis 7.7%, Polygala tenuifolia 5.5%, Curcuma longa 4.4%, Acorus tatarinowii 5.5%, processed Aconitum carmichaelii 2.2%, Achyranthes bidentata 5.5%, Pheretima aspergillum 7.7%, Zaocys dhumnades 4.4%, Scolopendra subspinipes 3.3%, Bombyx mori 4.4%, Manis pentadactyla 6.6%, Buthus martensii 4.4%, Pearl powder 2.1%, Arisaema cum bile 4.4%.

2. The drug for treating human cerebral infarction according to claim 1, characterized in that: The dosage form of the drug is powder, capsule, tablet or pill.

3. A method for preparing a drug for treating human cerebral infarction, used to prepare the drug for treating human cerebral infarction as described in claims 1-2, characterized in that: Includes the following steps: S1: Grind Astragalus membranaceus, Salvia miltiorrhiza, Carthamus tinctorius, Ligusticum chuanxiong, Bambusa textilis, Polygala tenuifolia, Curcuma longa, Acorus tatarinowii, processed Aconitum carmichaelii, and Achyranthes bidentata into powder and sieve to obtain the first group of medicinal powders; S2: Stir-fry earthworm, black-striped snake, and centipede with wine, then grind them into powder and sieve to obtain the second group of medicinal powder; S3: Stir-fry silkworm until it is dry, then grind it into powder and sieve to obtain the third group of medicinal powder; S4: After scalding the pangolin with sand, grind it into powder and sieve it to obtain the fourth group of medicinal powder; S5: Crush the whole scorpion, pearl powder, and bile-processed arisaema and sieve them to obtain the fifth group of medicinal powders; S6: Mix the above five groups of medicinal powders evenly to obtain the medicine.

4. The method for preparing a drug for treating human cerebral infarction according to claim 3, characterized in that: The mesh size for sieving described in S1, S2, S3, S4, and S5 is 80 to 200 mesh.

5. The method for preparing a drug for treating human cerebral infarction according to claim 3, characterized in that: The stir-frying in step S2 involves stir-frying the medicinal materials with rice wine until the surface is slightly dry.

6. The method for preparing a drug for treating human cerebral infarction according to claim 3, characterized in that: The sand-frying in step S4 involves stir-frying pangolin with hot sand until the surface puffs up and turns golden yellow.

7. The method for preparing a drug for treating human cerebral infarction according to claim 3, characterized in that: The stir-frying in step S3 involves placing the silkworm in a pot and stir-frying it over low heat until the surface turns slightly yellow.

8. The drug for treating human cerebral infarction according to claim 1, characterized in that: The drug is used in the preparation of a medicine for improving sequelae of cerebral infarction, wherein the sequelae of cerebral infarction include at least one of hemiplegia, dysphagia, and dysarthria.

Images